

Zevaskyn™ (prademagene zamikeracel) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician billing (HCPCS code: _____) Start Date: _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria**For Authorization:** (Approvals will be for 1 year for 1 treatment cycle)1. Clinical documentation (i.e., recent office notes) must be submitted with the request documenting the member's treatment plan. Is this information attached? Yes No

2. Please indicate the diagnosis and information

 Recessive Dystrophic Epidermolysis Bullous (RDEB)

- a. Will Zevaskyn™ be used for the treatment of wounds associated with RDEB? Yes No
- b. Was diagnosis confirmed by biallelic pathogenic variants in the collagen type VII alpha 1 chain (COL7A1) gene? Yes No (**results of genetic testing must be submitted with request**)
- c. Is Zevaskyn™ prescribed by a dermatologist at a qualified treatment center with expertise in the treatment of RDEB? Yes No
- d. Has member been counseled and will not use other epidermolysis bullous products (e.g., Vyjuvek®, Filsuvez®) on wounds treated with Zevaskyn™? Yes No
- e. Will Zevaskyn™ be administered at a Zevaskyn™ qualified treatment center? Yes No
Name of facility: _____
- f. Does the receiving facility have a mechanism in place to track the patient-specific Zevaskyn™ from receipt to storage to administration? Yes No

 Other: _____**Additional Information:** _____**Prescriber Signature:** _____ **Date:** _____*I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.*

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.